NC-SYNECHRON
Synechron, one of the fastest growing digital, business consulting and technology service providers, announced its corporate brand integration with Double Effect and Team Trade - companies it had acquired in the past few years, to further augment its consulting and technology capabilities. Post-acquisition, Double Effect and Team Trade were operating as independent entities and brands. However, this brand integration strategy will see both these entities merging into the parent company – Synechron, fortifying the overall consulting and technology business/practice. As part of Synechron’s recently announced ‘Power of 3’ strategy, this move is also aimed at providing all consulting and technology services combined with digital under a single brand umbrella in order to leverage Synechron’s robust brand equity, also fueling its ambition of being a billion dollar company by 2020.
Founded in 2003 in Amsterdam, Double Effect houses 100+ business consultants spread across eight global locations. The Dutch consulting firm works for banking and financial institutions including corporate, investment and retail banks, asset management companies and pension as well as insurance services. In 2013, Double Effect became part of the Synechron group.
Team Trade, founded in 2000, is a Paris-based firm specializing in business consulting and financial software integration. The firm has significant presence in Paris, Luxembourg, Milan, London, New York and Singapore covering the European, North American and Asian markets. Team Trade became part of the Synechron group in December 2014.
“Double Effect’s business consulting portfolio is perfectly aligned with the geographical, business, client and service coverage of Synechron. By operating as a consulting arm of the Synechron brand, all our client relationships and alliances will witness a greater value addition through our combined capabilities. We are very excited about this transformation,” said Bas Heijnen, Managing Director, Double Effec t on this occasion.
“Considering the roll out of the recent business transformation strategy by Synechron, this is the right time for brand integration of Team Trade with Synechron as providing technology and consulting services under the merged identity will have a positive impact in the eyes of clients and other stakeholders,” said Pascal Rellier, Managing Director, Team Trade .
“For Synechron, Double Effect and Team Trade, this mutually beneficial move is a major opportunity for offering a niche, augmented set of technology as well as consulting services for the financial services industry. This brand integration will add more depth to Synechron’s current value proposition and enable our global clients to avail business solutions with a 360-degree perspective, encompassing business consulting and technology combined with digital transformation services under a single roof,” commented Faisal Husain, Co-founder and Chief Executive Officer, Synechron .
This brand integration will come into effect on April 4, 2016 and will be a critical step for Synechron in order to strategically re-align its technology and consulting service capabilities in all its service lines.
About Synechron
Synechron, one of the fastest-growing digital, business consulting & technology services providers, is a $350 million firm based in New York. Since inception in 2001, Synechron has been on a steep growth trajectory. With 5,000+ professionals operating in 16 countries across the world, it has presence across USA, Canada, UK, France, The Netherlands, Switzerland, Luxembourg, Serbia, Germany, Italy, UAE, Singapore, Hong Kong, Japan, Australia and Development Centers in India. Visit us at www.synechron.com .
View source version on businesswire.com: http://www.businesswire.com/news/home/20160331005965/en/
Contact:
Synechron
Atul Tajave
Manager - Global Marketing &
Communication
synechron-mediarelations@synechron.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
